drugset
drugset / Trial / NCT05550363

A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2)

NCT05550363 ↗

Phase 3 Withdrawn EyePoint Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

A Phase 3, Prospective, Randomized, Double-masked, Placebo-controlled, Parallel-design, Multicenter Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated with Cataract Surgery

Timeline

Start
2022-09
Primary completion
2023-09
Completion
2023-09

Outcome

Outcome not reported

Stopped: “Not currently pursuing indication”

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 517 ug —

Indications

cataract